comprehensive -WSS

comprehensive

author：entertainment 2025-09-28 21:56:46 - browse：47

Peter Marks. -- health coverage from STAT — Peter Marks, Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration. Susan Walsh-Pool/Getty Images

Peter Marks wants drug developers to ask more stupid questions.

It’s part of the top Food and Drug Administration official’s plan to reinvigorate gene therapy, a field that has struggled despite significant technological advances. Some companies are shelving programs or going out of business, even when they have promising data.

The problems are numerous: The diseases are often exceptionally rare, limiting the potential market. Manufacturing at commercial quality is complex and expensive. Proving a drug works can be difficult, because there may be too few patients to run a traditional randomized study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Covid's long

hotspot

WSS

White House drug shortages task force keeps mum with Congress

Target recalls 2.2 million additional candles due to laceration, burn hazards

Ionis drug prevents swelling attacks due to hereditary angioedema

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Cord blood banking comes at a high cost to babies

Ionis drug prevents swelling attacks due to hereditary angioedema

explore

comprehensive

Wikipedia

Peter Hotez and the public health issue of online harassment

At ASCO, AstraZeneca reports strong data for breast cancer drug

Affirmative action in medical school literally saved lives

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Jerome Adams on the need for new antivirals for Covid

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

Alkermes shareholders re

Kim Kardashian sparks debate on benefits of full

Cancer drug shortages should be causing more outrage

Ionis drug prevents swelling attacks due to hereditary angioedema

leisure time

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Shifting the focus from loneliness to social health

How to increase colonoscopy rates? Looks like an AI can help

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

The history of OxyContin, told through Purdue Pharma documents

Pharma budget tightening trickles down to Doximity

focus

hotspot

hotspot

hotspot